查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2141740

Temozolomide膠囊市場：全球市場預測，2026-2032年

Temozolomide Capsules Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Temozolomide膠囊市場將成長至 29 億美元，複合年成長率為 7.20%。

主要市場統計數據
基準年 2025 17.8億美元
預計年份：2026年 18.8億美元
預測年份 2032 29億美元
複合年成長率 (%) 7.20%

Temozolomide膠囊：臨床應用及市場趨勢

Temozolomide膠囊是一種口服甲醇烷基化類抗癌藥物，主要用於治療某些惡性腦腫瘤，特別是膠質母細胞瘤和退行性星細胞瘤，通常與放射治療合併使用或作為放射線治療的一部分。其使用取決於治療指南、監管部門的批准、腫瘤科醫生的臨床實踐、患者的適應症以及非專利藥的供應。該藥物治療可能引起骨髓抑制、噁心、疲勞和其他副作用，因此臨床決策應在專科醫生的後續觀察下進行，血液檢查對於安全治療至關重要。

治療格局正朝著更協調的神經腫瘤治療方向轉變。

由於神經外科、放射腫瘤科、腫瘤內科、病理科和支持治療科室之間協作的加強，癌症治療方式正在改變。分子特徵分析，包括腫瘤生物標記（如MGMT啟動子甲基化和IDH狀態）的評估，在臨床適用的情況下，對預後和治療方案製定發揮越來越重要的作用。同時，口服給藥方式也對患者及其看護者提出了更高的要求，包括用藥依從性、藥物儲存、給藥方案管理以及併發症的預防。醫療資源的可近性仍然存在差異，因為專業的診斷、腫瘤藥房、放射治療設施和追蹤服務主要集中在資源豐富的地區。

在臨床監督下，人工智慧 (AI) 可輔助提高精準度、最佳化工作流程並確保安全。

人工智慧正透過影像分析、腫瘤分割、放射治療計劃輔助、觀察理解、臨床試驗匹配以及治療反應和毒性預測等方式為神經腫瘤學做出貢獻。在Temozolomide治療中，數據驅動型工具可以幫助臨床醫生在適用性評估和監測過程中整合影像、分子觀察、實驗室檢查結果和治療史。這些應用目前仍屬於輔助手段，而非替代方案。在人工智慧的輸出能夠真正影響醫療保健之前，跨不同人群的檢驗、透明的效能評估、資料管治、網路安全以及臨床醫生的審核都至關重要。雖然人工智慧可以改善藥物管理流程，但它並不能取代患者諮詢和後續觀察的必要性。

區域性見解：可用性取決於腫瘤治療基礎設施和保險報銷。

北米では、一般的に、神経腫瘍学の豊富な専門知識、分子検査、放射線治療の体制、専門薬局ネットワークの恩恵を受けていますが、経済的負担や保険適用範囲が治療の継続性に影響を与える可能性があります。欧州では、確立された臨床パスがある一方で、国によって償還制度、医薬品の調達、アクセス状況に違いが見られます。アジア太平洋地域では、先進的な腫瘍学システムが存在する一方で、サービスが急速に拡大しているもの、地方におけるアクセス、診断、治療費の負担能力には著しい格差が見られます。ラテンアメリカでは、専門医の育成が進められていますが、公共部門の資源制約や、放射線治療および医薬品の利用可能性の不均一さが、治療の継続性に影響を及ぼしています。中東では、資源が豊富な都市區の医療システムと、専門医のカバー率が限られている地域との間にばらつきが見られます。アフリカでは、診断サービス、腫瘍学インフラ、訓練を受けた人材、医薬品の入手可能性において顕著な格差に直面しており、統合的な能力構築が特に重要となっています。

集團洞察：經濟和政治聯盟塑造醫療保健系統優先事項

ASEAN域内では、医療財政、規制の成熟度、専門医の能力における違いが、多様なアクセス経路を生み出していますが、地域協力は調達や知識の交換を支援することができます。BRICS加盟国は、相当な科学,製造能力を有する一方で、各国の医療保障範囲、公共部門の能力、農村部へのアクセスにおいて大きな格差が見られます。欧州連合（EU）は、科学および規制面での共同取り組みの恩恵を受けていますが、各国の保険償還に関する決定が、実際の利用可能性に影響を与え続けています。G7諸国は概して、成熟した腫瘍医療システム、確立された研究ネットワーク、そして強力な医薬品安全性監視能力を有していますが、一方で、費用対効果やヘルスケアシステムの永續性に関する課題にも直面しています。GCC諸国は、比較的資源の充実した都市區のヘルスケアシステムを有していることが多い一方で、医療従事者の現地化や紹介体制は依然として重要な考慮事項となっています。NATO加盟国は多様なヘルスケアシステムを抱えており、同盟への加盟が均一なアクセスを意味するわけではありません。備え、国境を越えた調査、そして強靭なサプライチェーンは、引き続き重要なテーマとなっています。

國家概況：國家醫療保健系統影響治療的可近性和可近性。

在澳大利亞，雖然有專業的癌症治療服務，但由於地理位置分散，主要都會區以外的地區就醫較為困難。巴西擁有廣泛的臨床專業知識，但公共癌症治療系統和藥物取得途徑因地區而異。在加拿大，除了距離帶來的障礙外，各省的保險覆蓋範圍和服務可及性也存在差異。在中國，雖然癌症治療基礎設施和研究活動正在擴展，但大都會圈和發展中地區之間仍然存在差距。法國、德國、義大利和西班牙都擁有成熟的歐式癌症治療體系，但在保險報銷、處方流程、區域組織結構和等待時間等方面存在差異。在印度，雖然私立和學術機構都具備很高的能力，但人們在經濟承受能力和獲得醫療服務方面存在顯著差異。日本和韓國擁有先進的醫院癌症治療服務，但國家政策和保險報銷框架會影響治療的可及性。在墨西哥，雖然正在發展專業的癌症治療體系，但不同地區和醫療機構之間仍然存在差距。 roshia的醫療狀況、地理、醫療制度的差異、調整條件、醫療條件的集中度によって影響を受けています。英國では、體系化された臨床ガイドラインと専門的なサービが整備さがてなますが、醫療提供能力や待ち時間の問題により、醫療提供に影響が出ています。米國には神経腫了治療學に關する広範な専門知識と選摳肢がありますが、保険制度の設計、自己負擔得起費用、および格差が、病人の醫療へのakusesuや治療の外表に影響を及ぼす可能性があります。

領導者的行動重點：提高醫療服務的可近性、安全性和實證照護。

業界のリーダーは、経口抗がん剤について、安定した供給、品質が保証された製造、そして強靭な流通体制を優先すべきです。患者支援プログラムは、医療従事者の監督に取って代わるものではなく、服薬遵守、投与指示、毒性の認知、検査によるモニタリング、および看護者との連携を強化すべきです。病院や公衆衛生システムとの連携により、轉診途徑、分子検査、放射線治療の調整、および医療サービスが不十分な地域でのアクセスを改善することができます。エビデンスの創出においては、実臨床における安全性、治療の継続性、多様な集団における治療成績、およびAIを活用したツールの責任ある評価に焦点を当てるべきです。また、リーダーは、厳格な医薬品安全性監視と国内規制の遵守を維持しつつ、教育資料を現地の言語やヘルスリテラシーのニーズに合わせて調整する必要があります。

調查方法：基於證據的臨床和機構因素解讀

本執行摘要では、提供された市場定義（Temozolomideカプセル）に基づき、その使用に関連する確立された臨床的、規制的、および医療制度上の考慮事項を統合しています。本評価では、承認された治療上の役割、認められたモニタリング要件、腫瘍学インフラ、償還およびアクセス条件、地域ごとの医療制度の違い、ならびにがん治療における人工知能の文書化された応用例に重点を置いています。地域、グループ、および国ごとの観察結果は定性的かつ比較的なものであり、市場推計,予測、市場シェア、または製品別の商業性的ランキングを構成するものではありません。運用上または臨床上のいかなる決定も、現在の国内の附加檔、治療ガイドライン、地域の調達規則、および専門医の助言に基づいて確認される必要があります。

結論：協調的照護對於合理使用替Temozolomide至關重要。

Temozolomide膠囊仍是治療某些惡性腦瘤的重要口服藥物，但其臨床價值並非僅取決於藥物的可近性。適當的診斷、基於生物標記的治療計劃、與放射治療的協調、實驗室監測、用藥依從性支持以及不利事件的及時處理都至關重要。區域和國家在基礎設施、資金籌措和專科醫生能力方面的差異將繼續影響藥物的可近性。負責任地應用人工智慧、增加對腫瘤服務的投入以及建立健全的供應和支持體系，將有助於醫療管理者在確保臨床醫生主導決策的同時，提高治療的連續性和安全性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：Temozolomide膠囊市場：依劑量強度分類

  • 100 mg
  • 140 mg
  • 180 mg
  • 20 mg
  • 250 mg
  • 5 mg

第8章：Temozolomide膠囊市場：依應用領域分類

  • 間變性星狀細胞瘤
  • 膠質母細胞瘤
  • 惡性膠質瘤

第9章：Temozolomide膠囊市場：依最終用戶分類

  • 家庭醫療保健
  • 醫院
  • 腫瘤診所
  • 專業醫療中心

第10章：Temozolomide膠囊市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第11章：Temozolomide膠囊市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第12章：Temozolomide膠囊市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第13章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第14章：公司簡介

  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals Inc.
  • ANI Pharmaceuticals Inc.
  • Apotex Corp.
  • Cadila Pharmaceuticals Ltd.
  • Celon Laboratories Ltd.
  • Chartwell Life Molecules LLC
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Glarea Healthcare LLP
  • H. Lundbeck A/S
  • Hetero Labs Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Merck & Co. Inc.
  • Natco Pharma Limited
  • Reliance Life Sciences Pvt. Ltd.
  • Sandoz International GmbH
  • Spica Drugs Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

第15章 主要專家

Product Code: MRR-9C4233EE5E63

The Temozolomide Capsules Market is projected to grow by USD 2.90 billion at a CAGR of 7.20% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.78 billion
Estimated Year [2026] USD 1.88 billion
Forecast Year [2032] USD 2.90 billion
CAGR (%) 7.20%

Temozolomide Capsules: Clinical Role and Market Context

Temozolomide capsules are oral alkylating chemotherapy medicines used primarily in the management of certain malignant brain tumors, especially glioblastoma and anaplastic astrocytoma, typically alongside radiotherapy or as part of subsequent treatment. Their use is shaped by treatment guidelines, regulatory approvals, oncology capacity, patient suitability, and the availability of generic formulations. Clinical decisions require specialist oversight because treatment can cause myelosuppression, nausea, fatigue, and other adverse effects, with blood-count monitoring central to safe administration.

Treatment Pathways Are Shifting Toward More Coordinated Neuro-Oncology Care

The treatment landscape is changing through greater coordination among neurosurgery, radiation oncology, medical oncology, pathology, and supportive-care services. Molecular characterization, including assessment of tumor biomarkers such as MGMT promoter methylation and IDH status where clinically appropriate, increasingly informs prognosis and treatment planning. At the same time, oral administration places more responsibility on patients and caregivers for adherence, storage, scheduling, and recognition of complications. Access remains uneven because specialized diagnostics, oncology pharmacies, radiotherapy infrastructure, and follow-up services are concentrated in better-resourced settings.

Artificial Intelligence Supports Precision, Workflow, and Safety-With Clinical Oversight

Artificial intelligence is contributing to neuro-oncology through imaging analysis, tumor segmentation, radiotherapy planning support, pathology interpretation, clinical-trial matching, and prediction of treatment response or toxicity. For temozolomide therapy, data-driven tools may help clinicians combine imaging, molecular findings, laboratory results, and treatment history when assessing suitability and monitoring. These applications remain supportive rather than substitutive: validation across diverse populations, transparent performance evaluation, data governance, cybersecurity, and clinician review are essential before AI outputs influence care. AI can also improve medication-management workflows, but it does not remove the need for patient counseling and laboratory surveillance.

Regional Insights: Access Depends on Oncology Infrastructure and Reimbursement

North America generally benefits from extensive neuro-oncology expertise, molecular testing, radiotherapy capacity, and specialty-pharmacy networks, although affordability and insurance coverage can affect continuity. Europe combines established clinical pathways with differences in reimbursement, procurement, and access between countries. Asia-Pacific includes advanced oncology systems alongside rapidly expanding services and significant disparities in rural access, diagnostics, and treatment affordability. Latin America continues to develop specialist capacity, with public-sector resource constraints and uneven availability of radiotherapy and medicines influencing treatment continuity. The Middle East shows variation between well-resourced urban systems and settings with limited specialist coverage. Africa faces pronounced gaps in diagnostic services, oncology infrastructure, trained personnel, and medicine availability, making integrated capacity-building particularly important.

Group Insights: Economic and Political Alliances Shape Health-System Priorities

Within ASEAN, differences in health financing, regulatory maturity, and specialist capacity create varied access pathways, while regional cooperation can support procurement and knowledge exchange. BRICS members combine substantial scientific and manufacturing capabilities with major disparities in national coverage, public-sector capacity, and rural access. The European Union benefits from shared scientific and regulatory collaboration, but national reimbursement decisions continue to influence practical availability. G7 countries generally have mature oncology systems, established research networks, and stronger pharmacovigilance capabilities, alongside pressures related to affordability and health-system sustainability. GCC countries often have comparatively well-resourced urban healthcare systems, while workforce localization and referral capacity remain important considerations. NATO members span diverse health systems, so alliance membership does not imply uniform access; preparedness, cross-border research, and resilient supply chains remain relevant themes.

Country Insights: National Systems Drive Treatment Availability and Use

Australia combines specialist cancer services with geographic dispersion that can complicate access outside major centers. Brazil has broad clinical expertise but substantial regional variation in public oncology capacity and medicine access. Canada faces distance-related barriers and provincial differences in coverage and service organization. China has expanding oncology infrastructure and research activity, with continuing variation between metropolitan and less-developed areas. France, Germany, Italy, and Spain operate established European oncology systems, but reimbursement, prescribing pathways, regional organization, and waiting times differ. India has strong private and academic capabilities alongside pronounced affordability and access disparities. Japan and South Korea maintain advanced hospital-based cancer services, with national policy and reimbursement frameworks influencing treatment use. Mexico continues to develop specialist capacity while regional and institutional differences remain significant. Russia's access landscape is influenced by regional health-system variation, procurement conditions, and oncology-service concentration. The United Kingdom benefits from structured clinical guidance and specialized services, while capacity and waiting-time pressures affect delivery. The United States has extensive neuro-oncology expertise and treatment options, but insurance design, out-of-pocket costs, and disparities can affect patient access and adherence.

Action Priorities for Leaders: Strengthen Access, Safety, and Evidence-Based Care

Industry leaders should prioritize reliable supply, quality-assured manufacturing, and resilient distribution for oral oncology medicines. Patient-support programs should reinforce adherence, dosing instructions, toxicity recognition, laboratory monitoring, and coordination with caregivers without replacing clinician supervision. Partnerships with hospitals and public-health systems can improve referral pathways, molecular testing, radiotherapy coordination, and access in underserved regions. Evidence generation should focus on real-world safety, treatment persistence, outcomes across diverse populations, and responsible evaluation of AI-enabled tools. Leaders should also align educational materials with local languages and health-literacy needs while maintaining rigorous pharmacovigilance and compliance with national regulations.

Research Methodology: Evidence-Led Interpretation of Clinical and System Factors

This executive summary uses the supplied market definition-temozolomide capsules-and synthesizes established clinical, regulatory, and health-system considerations relevant to their use. The assessment emphasizes approved therapeutic roles, recognized monitoring requirements, oncology infrastructure, reimbursement and access conditions, regional health-system differences, and documented applications of artificial intelligence in cancer care. Regional, group, and country observations are qualitative and comparative; they do not constitute market estimates, forecasts, market shares, or product-specific commercial rankings. Any operational or clinical decision should be confirmed against current national labeling, treatment guidelines, local procurement rules, and specialist medical advice.

Conclusion: Coordinated Care Will Define Responsible Temozolomide Use

Temozolomide capsules remain an important oral component of treatment for selected malignant brain tumors, but their clinical value depends on more than medicine availability. Appropriate diagnosis, biomarker-informed planning, radiotherapy coordination, laboratory monitoring, adherence support, and timely management of toxicity are all essential. Regional and country differences in infrastructure, financing, and specialist capacity will continue to shape access. Responsible adoption of AI, investment in oncology services, and resilient supply and support systems can help leaders improve continuity and safety while preserving clinician-led decision-making.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Temozolomide Capsules Market, by Dosage Strength

  • 7.1. Introduction
  • 7.2. 100 Mg
  • 7.3. 140 Mg
  • 7.4. 180 Mg
  • 7.5. 20 Mg
  • 7.6. 250 Mg
  • 7.7. 5 Mg

8. Temozolomide Capsules Market, by Application

  • 8.1. Introduction
  • 8.2. Anaplastic Astrocytoma
  • 8.3. Glioblastoma Multiforme
  • 8.4. Malignant Glioma

9. Temozolomide Capsules Market, by End User

  • 9.1. Introduction
  • 9.2. Home Healthcare
  • 9.3. Hospitals
  • 9.4. Oncology Clinics
  • 9.5. Specialty Centers

10. Temozolomide Capsules Market, by Region

  • 10.1. Introduction
  • 10.2. Asia-Pacific
  • 10.3. North America
  • 10.4. Latin America
  • 10.5. Europe
  • 10.6. Middle East
  • 10.7. Africa

11. Temozolomide Capsules Market, by Group

  • 11.1. Introduction
  • 11.2. ASEAN
  • 11.3. GCC
  • 11.4. European Union
  • 11.5. BRICS
  • 11.6. G7
  • 11.7. NATO

12. Temozolomide Capsules Market, by Country

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. United Kingdom
  • 12.7. Germany
  • 12.8. France
  • 12.9. Russia
  • 12.10. Italy
  • 12.11. Spain
  • 12.12. China
  • 12.13. India
  • 12.14. Japan
  • 12.15. Australia
  • 12.16. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2025
  • 13.2. Market Concentration Analysis, 2025
    • 13.2.1. Concentration Ratio (CR)
    • 13.2.2. Herfindahl Hirschman Index (HHI)
  • 13.3. Recent Developments & Impact Analysis, 2025
  • 13.4. Product Portfolio Analysis, 2025
  • 13.5. Benchmarking Analysis, 2025

14. Company Profiles

  • 14.1. Accord Healthcare Ltd.
  • 14.2. Amneal Pharmaceuticals Inc.
  • 14.3. ANI Pharmaceuticals Inc.
  • 14.4. Apotex Corp.
  • 14.5. Cadila Pharmaceuticals Ltd.
  • 14.6. Celon Laboratories Ltd.
  • 14.7. Chartwell Life Molecules LLC
  • 14.8. Cipla Ltd.
  • 14.9. Dr. Reddy's Laboratories Ltd.
  • 14.10. Emcure Pharmaceuticals Ltd.
  • 14.11. Glarea Healthcare LLP
  • 14.12. H. Lundbeck A/S
  • 14.13. Hetero Labs Limited
  • 14.14. Hikma Pharmaceuticals PLC
  • 14.15. Intas Pharmaceuticals Ltd.
  • 14.16. Merck & Co. Inc.
  • 14.17. Natco Pharma Limited
  • 14.18. Reliance Life Sciences Pvt. Ltd.
  • 14.19. Sandoz International GmbH
  • 14.20. Spica Drugs Pvt. Ltd.
  • 14.21. Sun Pharmaceutical Industries Ltd.
  • 14.22. Taj Pharmaceuticals Limited
  • 14.23. Teva Pharmaceutical Industries Ltd.
  • 14.24. Viatris Inc.
  • 14.25. Zydus Lifesciences Ltd.

15. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Temozolomide Capsules Market, Years Considered for the Study
  • FIGURE 2. Global Temozolomide Capsules Market, Research Design
  • FIGURE 3. Global Temozolomide Capsules Market, Research Framework
  • FIGURE 4. Global Temozolomide Capsules Market, Data Triangulation
  • FIGURE 5. Global Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Temozolomide Capsules Market Size, by Dosage Strength, 2025 vs 2032 (%)
  • FIGURE 7. Global Temozolomide Capsules Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Temozolomide Capsules Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 9. Global Temozolomide Capsules Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Temozolomide Capsules Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 11. Global Temozolomide Capsules Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Temozolomide Capsules Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 13. Global Temozolomide Capsules Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Temozolomide Capsules Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 15. Global Temozolomide Capsules Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 16. Global Temozolomide Capsules Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Temozolomide Capsules Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Temozolomide Capsules Market Segmentation & Coverage
  • TABLE 2. Global Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 4. Global 100 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global 100 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global 100 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global 140 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global 140 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global 140 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global 180 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global 180 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global 180 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global 20 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global 20 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global 20 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global 250 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global 250 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global 250 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global 5 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global 5 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global 5 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 23. Global Anaplastic Astrocytoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Anaplastic Astrocytoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Anaplastic Astrocytoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Glioblastoma Multiforme Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Glioblastoma Multiforme Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Glioblastoma Multiforme Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Malignant Glioma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Malignant Glioma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Malignant Glioma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 33. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global Oncology Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Oncology Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Oncology Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Specialty Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Specialty Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Specialty Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Temozolomide Capsules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Asia-Pacific Temozolomide Capsules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Asia-Pacific Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 48. Asia-Pacific Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 49. Asia-Pacific Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 50. North America Temozolomide Capsules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. North America Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 52. North America Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 53. North America Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 54. Latin America Temozolomide Capsules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Latin America Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 56. Latin America Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 57. Latin America Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 58. Europe Temozolomide Capsules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Europe Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 60. Europe Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 61. Europe Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 62. Middle East Temozolomide Capsules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Middle East Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 64. Middle East Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 65. Middle East Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 66. Africa Temozolomide Capsules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Africa Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 68. Africa Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 69. Africa Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 70. Global Temozolomide Capsules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. ASEAN Temozolomide Capsules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. ASEAN Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 73. ASEAN Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 74. ASEAN Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 75. GCC Temozolomide Capsules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. GCC Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 77. GCC Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 78. GCC Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 79. European Union Temozolomide Capsules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. European Union Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 81. European Union Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 82. European Union Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 83. BRICS Temozolomide Capsules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 84. BRICS Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 85. BRICS Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 86. BRICS Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 87. G7 Temozolomide Capsules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. G7 Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 89. G7 Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 90. G7 Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 91. NATO Temozolomide Capsules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. NATO Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 93. NATO Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 94. NATO Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 95. Global Temozolomide Capsules Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 96. United States Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 97. United States Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 98. United States Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 99. United States Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 100. Canada Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 101. Canada Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 102. Canada Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 103. Canada Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 104. Mexico Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 105. Mexico Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 106. Mexico Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 107. Mexico Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 108. Brazil Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 109. Brazil Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 110. Brazil Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 111. Brazil Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 112. United Kingdom Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 113. United Kingdom Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 114. United Kingdom Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 115. United Kingdom Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 116. Germany Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 117. Germany Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 118. Germany Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 119. Germany Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 120. France Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 121. France Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 122. France Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 123. France Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 124. Russia Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 125. Russia Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 126. Russia Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 127. Russia Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 128. Italy Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 129. Italy Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 130. Italy Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 131. Italy Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 132. Spain Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 133. Spain Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 134. Spain Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 135. Spain Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 136. China Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 137. China Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 138. China Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 139. China Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 140. India Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 141. India Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 142. India Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 143. India Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 144. Japan Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 145. Japan Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 146. Japan Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 147. Japan Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 148. Australia Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 149. Australia Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 150. Australia Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 151. Australia Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 152. South Korea Temozolomide Capsules Market Size, 2017-2032 (USD Million)
  • TABLE 153. South Korea Temozolomide Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 154. South Korea Temozolomide Capsules Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 155. South Korea Temozolomide Capsules Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 156. Global Temozolomide Capsules Market Share, by Key Player, 2025
  • TABLE 157. Global Temozolomide Capsules Market, Key Experts